By using our site you agree to our Data protection and accept the use of cookies.

Dermapharm – pharmaceutical excellence „Made in Germany“

Dermapharm, a family-run pharmaceutical company founded in 1991, has its headquarters in Grünwald near Munich and its main production site in Brehna near Leipzig.

At the beginning of 2018, extensive preparations were made for an IPO to ensure the company's future development. Since 9 February 2018, the shares of Dermapharm Holding SE, which is also the parent company of the group, have been listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange.

Dermapharm's integrated business model comprises its own development and production as well as the distribution of a broad spectrum of drugs and health products. Dermapharm has around 950 marketing authorizations for more than 250 active pharmaceutical ingredients. This diverse range and its commitment to Germany as the central production location make the company unique.

Today, Dermapharm occupies a leading position in numerous markets. With a consistent research and development strategy and numerous successful product and company acquisitions in recent years, Dermapharm has continuously optimized its business activities and ensured organic growth in the long term.

In order to continue to grow profitably in the future, Dermapharm's strategy is based on three pillars: consistent development of new products for sustainable market segments, expansion of the international presence and further successful acquisitions.

Homogeneous, dynamic development and the principle of sustainability are the keys to Dermapharm's success - today and in the future.